Medplus Health Services announced that its subsidiary, Optival Health Solutions Private Limited, has received a three-day suspension order for a drug license at one of its stores in Tamil Nadu. The suspension, issued by the Assistant Director of Drugs Control Administration, Zone III, Tamil Nadu, affects a store located in MGR Nagar.

Violation Details

The suspension order, received on July 22, 2025, cites violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. While the specific nature of the violation was not disclosed, the company has acknowledged the regulatory action in its filing to the stock exchanges.

Financial Impact

Medplus Health Services estimates a potential revenue loss of approximately Rs. 3.03 lakhs due to this temporary suspension. This figure reflects the immediate financial impact of the regulatory action.

Regulatory Compliance

The company's prompt disclosure of this incident aligns with the Securities and Exchange Board of India (SEBI) regulations, specifically Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This transparency is further reinforced by recent SEBI circulars aimed at enhancing disclosure practices among listed entities.

Company Response

Manoj Kumar Srivastava, Company Secretary & Compliance Officer of Medplus Health Services, signed off on the regulatory filing. The company has stated that details of the suspension will be available on its official website, as well as on the websites of the BSE and NSE.

This incident underscores the regulatory challenges faced by pharmaceutical retail chains and the importance of maintaining strict compliance with drug laws and regulations. As the suspension is limited to three days and affects only one store, the long-term impact on Medplus Health Services' operations is likely to be minimal. However, it serves as a reminder of the ongoing regulatory scrutiny in the pharmaceutical retail sector.

Investors and stakeholders will be watching closely to see if this incident leads to any broader implications for the company's operations or if it prompts any internal reviews of compliance procedures across its network of stores.

Medplus Health Services announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at five retail pharmacy outlets in Karnataka and Telangana. The suspensions, ranging from 2 to 7 days, were issued between July 10-14, 2025, under the Drugs and Cosmetics Act.

Suspension Details

The company disclosed the following information about the suspensions:

Regulatory Compliance

The suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. MedPlus Health Services has reported this development in compliance with SEBI regulations, specifically Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Impact

The company estimates potential revenue losses totaling approximately ₹4.78 lakh across the affected stores. This figure includes the specified losses for the three stores mentioned in the LODR filing, as well as the estimated losses for the two additional stores mentioned in the news update.

Transparency and Disclosure

MedPlus Health Services has stated that the details of these suspensions will be available on the company's website ( www.medplusindia.com ) as well as on the websites of BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Ltd. ( www.nseindia.com ).

Investors and stakeholders are advised to monitor these official channels for any further updates or clarifications regarding this matter.